Durstenfeld MS, et al. - In this retrospective cohort study, researchers report contemporary mineralocorticoid receptor antagonists (MRA) prescription for heart failure patients before and after the full scope of hospitalizations. They also focused on the link between MRA discharge prescription and post-hospitalization consequences. They included 1,500 hospitalizations of 1,009 unique patients with heart failure with a reduced ejection fraction (HFrEF), with no MRA contraindication, with a mean age of 71.9 ± 13.6 years and 29.5% being female. They found no link between MRA prescription at discharge and death or readmission at 30 and 180 days, and no interaction with principal/secondary diagnosis was found. Nonreceipt of MRA prior to or following hospitalization was reported in 75% of hospitalized HFrEF patients, and MRA was not started in approximately 90% of eligible patients. The experts concluded that hospitalization possibly is an opportunity to start guideline-directed heart failure treatment since no signal was found for short-term harm postdischarge.